Immuron Targets Multi-Billion-Dollar Travel Health Opportunity with Travelan®

Immuron's flagship product, Travelan, is targeting a global travellers' diarrhoea market estimated at $3.31 billion - and growing. Designed as a preventive rather than a cure, Travelan uses hyperimmune bovine antibodies to bind and neutralise the bacteria responsible for up to 80% of cases, before symptoms even begin. Already approved or licensed in Australia, Canada, and the United States, the product is backed by a scalable oral antibody platform with broad potential applications beyond travel health.

Read the Full Article Here